8I7T

The crystal structure of human abl1 kinase domain in complex with ABL1-B4

Summary for 8I7T

• Entry DOI: 10.2210/pdb8i7t/pdb
• Descriptor: Tyrosine-protein kinase ABL1, [3-[5-[5-(dimethylcarbamoyl)pyridin-3-yl]-1H-pyrrolo[2,3-b]pyridin-3-yl]-4-methoxy-phenyl] ethanesulfonate (2 entities in total)
• Functional Keywords: covalent kinase bcr-abl, transferase
• Biological source: Homo sapiens (human)
• Total number of polymer chains: 2
• Total formula weight: 64279.33

Authors

Zhu, C.,Zhang, Z. (deposition date: 2023-02-02, release date: 2024-10-23)

Primary citation

Sun, J.,Lou, L.,Zhu, C.,Chen, P.,Tang, G.,Gu, M.,Xia, S.,Dong, X.,Zhang, Z.M.,Gao, L.,Yao, S.Q.,Xiao, Q.
Rationally designed BCR-ABL kinase inhibitors for improved leukemia treatment via covalent and pro-/dual-drug targeting strategies.
J Adv Res, 2024

PubMed Abstract: Chronic Myeloid Leukemia (CML) is a blood cancer that remains challenging to cure due to drug resistance and side effects from current BCR-ABL inhibitors. There is an urgent need for novel and more effective BCR-ABL targeting inhibitors and therapeutic strategies to combat this deadly disease.

PubMed: 39255927
DOI: 10.1016/j.jare.2024.09.008

Experimental method

X-RAY DIFFRACTION (2.80004960558 Å)